Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Ophthalmic Drug Delivery Systems01:23

Ophthalmic Drug Delivery Systems

Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
Graves' Disease I: Introduction01:28

Graves' Disease I: Introduction

Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence in...
Cushing Syndrome I: Introduction01:26

Cushing Syndrome I: Introduction

Cushing syndrome refers to the collection of clinical manifestations that arise when tissues are exposed to excessive amounts of cortisol or cortisol-like medications over an extended period. Cortisol, a glucocorticoid produced by the adrenal cortex, regulates metabolism, immune responses, and the body’s adaptation to stress. When its concentration remains chronically elevated, these physiological pathways become dysregulated, resulting in the characteristic features of the syndrome.Exogenous...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety and Feasibility of the Exchange Procedure for the Travoprost Intracameral Implant for Open-Angle Glaucoma or Ocular Hypertension.

Ophthalmology and therapy·2026
Same author

Administration of the Travoprost Intracameral Implant in an Office-Based Surgery Setting.

Ophthalmology and therapy·2025
Same author

Six-Month Outcomes from a Prospective, Randomized Study of iStent infinite Versus Hydrus in Open-Angle Glaucoma: The INTEGRITY Study.

Ophthalmology and therapy·2025
Same author

Aqueous Humor Concentrations of Travoprost Free Acid and Residual Drug in Explanted Implants from Patients Administered a Travoprost Intracameral Implant.

Ophthalmology and therapy·2025
Same author

Safety and efficacy of travoprost intracameral implant administered in combination with cataract surgery.

Therapeutic advances in ophthalmology·2025
Same author

Interventional Glaucoma: Improving the Patient-Provider Educational Exchange.

Clinical ophthalmology (Auckland, N.Z.)·2024
Same journal

Correlations between Clinical Activity Score and Serological and Radiological Data in Treatment-naïve Ethnic Han Chinese Thyroid Eye Disease.

Ophthalmic research·2026
Same journal

Stem Cell Based Interventions for Retinal Ganglion Cell Protection and Regeneration in Glaucoma: A Review of Current Evidence and Future Directions.

Ophthalmic research·2026
Same journal

Eye-Tracking Reading Patterns as Correlates of Clinical Measures in Glaucoma.

Ophthalmic research·2026
Same journal

A Matching-Adjusted Comparison of Faricimab and Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema.

Ophthalmic research·2026
Same journal

Ab Externo Continuous Pressure Technique for Descemet Membrane Endothelial Keratoplasty in Vitrectomized Eyes.

Ophthalmic research·2026
Same journal

Longitudinal change in corneal curvature and Fourier indices after corneal suture removal in corneal lacerations.

Ophthalmic research·2026
See all related articles

Related Experiment Video

Updated: May 31, 2026

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

Steroid-induced iatrogenic glaucoma.

M Reza Razeghinejad1, L Jay Katz

  • 1Department of Ophthalmology, Shiraz University of Medical Sciences, Shiraz, Iran.

Ophthalmic Research
|July 16, 2011
PubMed
Summary
This summary is machine-generated.

Steroids can induce elevated intraocular pressure (IOP) in susceptible individuals, mimicking glaucoma. Close monitoring and prompt intervention are crucial for managing steroid-induced ocular hypertension.

More Related Videos

A Reversible Silicon Oil-Induced Ocular Hypertension Model in Mice
09:03

A Reversible Silicon Oil-Induced Ocular Hypertension Model in Mice

Published on: November 15, 2019

Related Experiment Videos

Last Updated: May 31, 2026

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

A Reversible Silicon Oil-Induced Ocular Hypertension Model in Mice
09:03

A Reversible Silicon Oil-Induced Ocular Hypertension Model in Mice

Published on: November 15, 2019

Area of Science:

  • Ophthalmology
  • Endocrinology

Background:

  • Steroids can induce elevated intraocular pressure (IOP) in susceptible individuals, mimicking primary open-angle glaucoma.
  • Approximately 5% of the population are high steroid responders, experiencing significant IOP elevation.
  • Steroid-induced IOP elevation can occur within days to weeks of administration and may necessitate long-term management.

Purpose of the Study:

  • To review the clinical implications of steroid-induced ocular hypertension.
  • To discuss the mechanisms, risk factors, and management strategies for steroid-induced glaucoma.

Main Methods:

  • Review of existing literature on steroid-induced glaucoma.
  • Analysis of clinical observations regarding intraocular pressure response to steroids.
  • Evaluation of treatment outcomes for elevated IOP in patients using steroids.

Main Results:

  • Steroid administration can lead to IOP elevation in 20-65% of patients, with 75% requiring IOP-lowering therapy within 3 years.
  • Decreased trabecular meshwork outflow is the primary suspected mechanism for steroid-induced IOP elevation.
  • While most cases resolve after steroid cessation, 1-5% may require surgical intervention.

Conclusions:

  • Susceptible individuals require close monitoring for IOP changes during steroid therapy.
  • Management involves considering lower-potency steroids, steroid-sparing agents, or surgical options if medical therapy fails.
  • Early intervention and removal of residual steroids can aid in IOP normalization.